was important would joining immunotherapy a of for like of and our I priorities. highlight XXXX made T-cell four progress and year morning. that to significant you, thanks prioritization John all strategic Thank all this advancement you on to of programs. we've strategy us
innovative into position cash our to our advance to tab-cel we extended continue XXXX QX, T-cell also have immunotherapy off-the-shelf leverage our and experience We platform.
anticpated milestones reviewing start for progress and recent momentum, tab-cel. let the significant highlights, this on me and by Building
We X post-transplant in Epstein-Barr clinical a the Phase EBV patients with disease associated conducting PTLD lymphoproliferative setting. with in trial or factory are currently or tab-cel virus relapsed
on in actively remains FDA BLA sites States to Atara half in currently the and XX to track a in to patients Europe. of submissions open United the XXXX. and have are the Australia, the Canada tab-cel sites enrolling We additional U.S. preparing and second initiate
to this end, countries several CTA Europe in of XXXX, clinical and sites XXXX. in of submitted application December us trial European Towards open we in November which will to clinical allow
have we we mentioned, Austria sites just the meet excited to are plan on track initiate Indeed, to Phase of in are additional We as are they and support phase patients tab-cel I will totality expanded required analysis. enrolment to number we BLA full pre-BLA XXXX. the half which X and including SOT the access of during our HCT growth, We submissions we for prior submission plan a collaborators the FDA the of phase patients with our second and generated, hold X U.K. recently or being CTA received to with the discuss EBV added as X positive program. necessary Spain. meeting study These data, to interim not PTLD academic tab-cel and be the the the to MSK approval whether in a X study for phase of continue
annual PTLD relapsed/refractory including safety clinical EBV-associated XX data diseases, EBV-associated we EBV+ patients with results long meeting. patients diseases. EAP XXXX a XX These from with in and As safety for recently December term for data XX and patients presented with findings most ASH data other reminder, compiled efficacy at for diverse
participating to well-tolerated generally study. this that demonstrate data in The was patients that tab-cel all
cohort overall of positive eligibility tab-cel criteria was the X met for a the study. XX% would XX group The HCT with with estimated PTLD phase overall Importantly, survival XX%. ongoing of rate likely EBV in a patients have two-year for response
rate For survival response cohort, two-year was estimated XX%. was SOT overall overall and XX% the
multiple also access or for a activities expand to We EMA. PIP in submitted designed Investigation to Europe. to engage Pediatric tab-cell Plan Atara patients recently in
PIP, with plans approval EMA authorization marketing the tab-cel to in submit of PTLD for applications EBV+ EU Atara Following XXXX. patients
multi-cohort The data date disease. half EBV SPU our six in with EAP up the additional enrolment a support to clinical and diseases. of study to of the potential initiate therapy several expect as a to other Phase second we programs of tab-cel tab-cel XXXX, EBV+ generated ultra-rare associated also transformative X including In
study with a enrolled we or of tab-cel carcinoma planned therapy had addition, EBV-associated combination Xb/X recurrent in patients Phase clinical of the portion platinum-resistant nasopharyngeal in Xb NPC. Phase anti-PD-X In the final the patient in with
will Prior immunotherapy Xa for safety the portion with the we evaluating in evaluate Xb initial patients label of data of of allogeneic NPC of multi-center treatment Phase that well XXXX the clinical X study progressive I we to Recall and progressive turn early or dose-escalation multiple Phase will from as ECTRIMS Phase of reported patients starting to now T-cell relapsed study, results landscape. refractory ATAXXX with open encouraging ATAXXX the form as sclerosis. MS. the efficacy
improvement up dose was showed clinical at ATAXXX cohort define cohort one MS. criteria, the in initiate selected six [ph] the course to out improvement double-blind, of two In a patient results progressive X with cohort this months. six part Xb study. of the also was reported placebo-controlled we We XX at X, This six We improvement in inpatient using ECTRIMS. with the recently four the randomized, months of cohort patient dose lowest at six months. Phase Safety of well maintained clinical reached that tolerated follow dose
on improvement to one Phase of an of out predetermined initiate safety clinical and in profile clinical than based for site. three six the cohort criteria acceptable achieving patient study Xb was X X achieving decision months Our more our at
for half XX-months cohorts expect to clinical six XXXX. XXXX, a up all for we the at in data force follow including second up months ahead, dated cohorts appropriate Looking present follow in all and of
of the study in portion to study, is X extension patients dose Xa complete four to annually for which the of portion one re-treated a the cohort open-label in patients up the be designed allow dose retreated year escalation using recently the years. to who Phase we Additionally, first
We initiate Phase the leading in randomized, of quarter Xb enrollment or study expecting for of placebo-controlled Australia. participate U.S. this we XXXX. an and third a track in activation is Site to process of also second are the increased to ATAXXX number and on MS centers study in
a Trends EBV In infection review connection leading published Medicine experts MS. addition, the Atara’s in regarding in Molecular between mechanistic article recently and
team third-party with treated relapsed/refractory platforms. study clinical T partially meeting from made off-the-shelf, with a allogeneic patient B-cell Therapy let's all Transplantation CDXX T-cells the primary T Cellular last in an EBV and At malignancies HLA XXXX Now donor EBV discuss an CAR or academic matched week, CAR donor presented
EBV first received six manufactured EBV CDXX matched with partially this HLA cells patients in-human for from CAR donors. In CAR T Investigators out T of complete cells who study, third-party observed this durable five CDXX responses
No CART cytokine who release no was T CDXX observed Grade EBV CDXX doses. EBV multiple syndrome third-party and in observed toxicities Also, with or above CAR patients X, dose-limiting donor post-infusion cells. no received neurotoxicity were confirmed GvHD
T patients manufactured who NHL, with with observed response months of for received with survival also complete out XX.X CAR cells out third-party median out patients XXX% one of CLL one up from including, EBV of CDXX NHL Importantly, with X donors X in CLL. partially of and CR responses investigators HLA in patient and four matched follow responses durable four
risk has this toxicity durable with immunotherapies from and and initial Findings proof-of-principle generate platform high that provide of EBV an study allogeneic low responses, to clinical off-the-shelf, T-cell delivery potential the patients. happy to CAR T
help to to make CAR candidates. continue We progress advancing T the our in
as physiologic novel domain We targeted as intrinsic patients greater microenvironment. expect including a collaborators of program advanced tumor is CAR a MSK the persistence of T knock signaling inhibition more in an that quarter that provide and receptor with next-generation FDA may mesothelioma. PD-X designed that to negative third [Ph] second This mesothelin to offer will submit the the co-stimulatory an T-cell and or solid ATAXXXX, incorporates checkpoint technologies autologous in dominant well for XXX XXXX our IND
studies enabling an allogeneic we CAR ATAXXXX, for with at next-gen EBV ATAXXXX. off-the-shelf same Furthermore, mesothelin preclinical the T technologies CAR targeted started have T IND
preclinical incorporates CAR started targeted have IND studies enabling CDXX ATAXXXX that EBV we and addition, T XXX. In for
T We and engine differentiated characteristics. T-cell, as leveraging EBV CAR favorable for off-the-shelf and platform believe, an continued EBV has is tremendous potential innovation, allogeneic safety, persistence Atara’s expansion, trafficking
Such Oaks in a clinical positional close manufacturing [Ph] capabilities one to a facility CMC T-cell and up T dedicated immunotherapies quality has a under current potential robust demand. Southern regulatory multiple CAR processes, preclinical roof. flexibility of integrates enables happy and and scale integration commercial Our control science, and future and research, support to produce and and development process
demonstrated been in manufacturing with capabilities improvement our tab-cel. yield platform recently of our efficiency The with manufacturing significant has
XXX over make to us single enabling now of from is process donor leukapheresis. stage commercial Our doses a
cost process of we will commercial to of believe our time, goods similar for profile those Over manufacturing allow biologics.
program we potential potential immunotherapy. Not from with opportunities T-cell access surprisingly, platform interest for partnership in a Phase validation activities a competitive in off-the-shelf strong addition, significant partners progressing off-the-shelf, portfolio. are advantage level In creating see to we product X T-cell a lead we allogeneic already seeing of also Atara and T-cell manufacturing have well, we commercial the are and for current
advances commercialization pleased brings On new the very for activities commercialization month, experience as oncology, neuroscience front, tab-cel. extensive Kristin Commercial Yarema the the operational Atara, are to Officer. hematology, we welcome disease are company Dr. autoimmune earlier valuable this as Chief Yarema to which and
We technical well Atara’s appointed role. you Officer operations [Ph] knew across officer Joe Hall platform, also on company created operation officer and Chief to excellence the programing to continue chief chief technical this have operational new drive a Operations you to like i Newell,
Turning positions. second million ended of of XX, cash, totalling short [ph] We million as cash compared investments quarter $XXX.X with to We $XXX.X term into and September XXXX. runaway equivalents, to extended the our as XXXX. XXXX financial cash
year, hard promising cash positioned XXXX in $XXX.X proceeds delivering work of of lead the exercise well including this option closing, pipeline tremendous tab-cel proforma programs other from progress made as the we XX, all has and on note, In January ATM advancing for further us our Of million. December XXXX XXXX and Atara’s success key and milestones investments was candidate, for for employees.
the now the back to the the I Q&A turn portion of begin to call Operator? operator call.
